Opus Genetics (IRD) Invested Capital (2010 - 2026)

Opus Genetics (IRD) has 17 years of Invested Capital data on file, last reported at -$45.8 million in Q1 2026.

• Invested Capital for Q1 2026 came in at -$45.8 million, down 357.68% year-over-year; the trailing twelve-month figure through Mar 2026 was -$45.8 million (down 357.68% YoY), and the FY2025 annual result was $15.3 million, up 128.26% from the prior year.
• Invested Capital eased to -$45.8 million in Q1 2026 per IRD's latest filing, from $15.3 million in the prior quarter.
• Over five years, Invested Capital peaked at $50.4 million in Q3 2023 and troughed at -$45.8 million in Q1 2026.
• A 5-year average of $25.9 million and a median of $29.3 million in 2025 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2023 and 2026: Invested Capital surged 324.14% in 2023, then slumped 357.68% in 2026.
• A 5-year view of Invested Capital shows it stood at $46.2 million in 2022, then advanced by 7.93% to $49.9 million in 2023, then plunged by 86.53% to $6.7 million in 2024, then soared by 128.26% to $15.3 million in 2025, then slumped by 398.64% to -$45.8 million in 2026.
• Business Quant data shows IRD's Invested Capital at -$45.8 million in Q1 2026, $15.3 million in Q4 2025, and $27.3 million in Q3 2025.